A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
In dendritic cell (DC)-based cancer immunotherapy, it is important that DCs present peptides derived from tumor-associated antigens on MHC class I, and activate tumor-specific cytotoxic T lymphocytes (CTLs). However, MHC class I generally present endogenous antigens expressed in the cytosol. We therefore developed an innovative approach capable of directly delivering exogenous antigens into the cytosol of DCs; i.e., a MHC class I-presenting pathway. In this study, we investigated the effect of antigen delivery using perfluoropropane gas-entrapping liposomes (Bubble liposomes, BLs) and ultrasound (US) exposure on MHC class I presentation levels in DCs, as well as the feasibility of using this antigen delivery system in DC-based cancer immunotherapy. DCs were treated with ovalbumin (OVA) as a model antigen, BLs and US exposure. OVA was directly delivered into the cytosol but not via the endocytosis pathway, and OVA-derived peptides were presented on MHC class I. This result indicates that exogenous antigens can be recognized as endogenous antigens when delivered into the cytosol. Immunization with DCs treated with OVA, BLs and US exposure efficiently induced OVA-specific CTLs and resulted in the complete rejection of E.G7-OVA tumors. These data indicate that the combination of BLs and US exposure is a promising antigen delivery system in DC-based cancer immunotherapy.
Suzuki
Ryo
R
Department of Biopharmaceutics, School of Pharmaceutical Sciences, Teikyo University, Sagamiko-cho, Sagamihara, Kanagawa, Japan.
Oda
Yusuke
Y
Utoguchi
Naoki
N
Namai
Eisuke
E
Taira
Yuichiro
Y
Okada
Naoki
N
Kadowaki
Norimitsu
N
Kodama
Tetsuya
T
Tachibana
Katsuro
K
Maruyama
Kazuo
K
D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D000941:Antigens / Q000008:administration & dosage* / Q000276:immunology / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003601:Cytotoxicity Tests, Immunologic; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation; D004705:Endocytosis / Q000187:drug effects / Q000276:immunology; D005466:Fluorocarbons / Q000737:chemistry; D016233:Immunotherapy, Active / Q000379:methods*; D007376:Interleukin-2 / Q000378:metabolism; D008081:Liposomes / Q000737:chemistry; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D010713:Phosphatidylcholines / Q000737:chemistry; D010714:Phosphatidylethanolamines / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry; D019810:Sodium Azide / Q000494:pharmacology; D016019:Survival Analysis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014465:Ultrasonics
D000941:Antigens; D019496:Cancer Vaccines; D005466:Fluorocarbons; D007376:Interleukin-2; D008081:Liposomes; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; C038089:1,2-distearoylphosphatidylethanolamine; D011092:Polyethylene Glycols; C028210:monomethoxypolyethylene glycol; D010047:Ovalbumin; D019810:Sodium Azide; C042852:perflutren; C010942:1,2-distearoyllecithin